Trials / Recruiting
RecruitingNCT06233292
A Study of ZG005 in Patients With Advanced Solid Tumors
A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 484 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ZG005 Powder for Injection | The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks. |
| BIOLOGICAL | ZG005 Powder for Injection | Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks. |
Timeline
- Start date
- 2022-06-17
- Primary completion
- 2026-01-01
- Completion
- 2026-01-01
- First posted
- 2024-01-31
- Last updated
- 2024-06-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06233292. Inclusion in this directory is not an endorsement.